Canada health panel says Vioxx pain drug safe enough

	Tweet

A Canadian expert advisory panel recommended on Thursday that Merck & Co. Inc.’s arthritis drug Vioxx be allowed back on the market despite the possibility of cardiovascular risks.

The panel also recommended that Pfizer Inc.’s rival pain medicine Celebrex be allowed to stay on the market but that Pfizer’s Bextra, another arthritis drug, be kept off the market.

The panel met at the government’s request last month to study the risks of the three drugs, known as COX-2 inhibitors, following reports of increased Heart disease and Stroke.

Merck voluntarily withdrew Vioxx from the market last September because of concern about such reports.

On April 7, Pfizer Canada announced the suspension of its Bextra, following the United States’ lead. It continued to sell Celebrex, but under restrictions.

The panel was unanimous on Thursday in recommending that Celebrex continue to be sold. It said the increased risk of cardiovascular disease was similar to that of other pain medicine while gastrointestinal harm appeared to be less.

“Patients benefit from having a variety of drugs to choose from for pain relief,” the report said.

By a vote of 12 to 1, the body recommended that Merck’s Vioxx be allowed back on the market, for the same reasons. The lone dissenter said evidence suggested that Vioxx had a higher risk of cardiovascular harm than Celebrex, especially at higher doses.

The vote was 8 to 5 against the reintroduction of Bextra, in part because there was not enough information available yet and because of a possible risk of a rare but serious skin disorder.

The panel recommended that warnings about the risks of Celebrex and Vioxx be added to the material given to patients. 

RELATED STORIES:
FDA approves Noxafil (posaconazole) to prevent invasive fungal infections   How to Prevent Morphine ‘Tolerance’   Many don’t disclose foregoing drugs   Big Drugs: A Bitter Pill   Dutch re-open some farms after dioxin scare   FDA wants asthma drug withdrawn   Vaccine thwarts drug-resistant pneumonia, meningitis   New rabies vaccine promising for wildlife   Drug firms offer saving card for U.S. uninsured   Pfizer Endometriosis Pain Drug Gets OK’d   FDA chief to meet with top lawmaker about Vioxx   More research needed on painkiller safety

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]